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Purpose: Kashin-Beck Disease (KBD) is an osteoarthropathy
of uncertain etiology that is endemic to the central and northwest
regions of China. Affected individuals have varying degrees of joint
deformity and limited joint mobility. Until now, the gold standard for
the diagnosis of KBD has been based on radiographic and clinical
examination features. Nevertheless, it is still difﬁcult for grass-
roots health care workers and medical researchers to diagnose
KBD. We studied the relationship of one of the signs of KBD—
brachydactyly, and the range of motion (ROM) at 8 joint sites. Our
long-term goal is to improve the sensitivity and speciﬁcity of the
screening tools for KBD.
Methods: 125 subjects from the Shangqiu village located in
Shaanxi province were involved in this study. All study proce-
dures were approved by the Xi’an Jiongtong University and Duke
University Institutional Review Boards. Informed consent, physical
examination data, and hand X-ray images were collected. At the
same time, saliva and nail samples were collected for genetic and
biochemical analyses. Brachydactyly was identiﬁed by the inability
of the ﬁngers (of either hand) to ﬂex sufﬁciently to touch the palm
beyond the transverse skin fold of the hand. ROM was quanti-
ﬁed as normal, mildly restricted, moderately restricted or severely
restricted for 8 joint sites (cervical spine, shoulder, elbow, wrist,
hip, knee, tibiotalar and subtalar ankle, and metatarsalphalangeal
foot joint). Non-parametric rank sum test were used to evaluate
the severity of ROM abnormalities between the two groups. All
statistical analyses were performed with JMP 7.0.
Results: A total of 47 (37.6%) subjects met criteria for brachy-
dactyly. The mean age and body mass index were similar for
the brachydactyly and non-brachydactyly groups (Figure 1). The
joint ROM was signiﬁcantly different between the brachydactyly
and non-brachydactyly groups for all joint sites except the hip
Figure 1
Figure 2. Joint range of motion of 8 joint sites.
(shoulder and metatarsalphalangeal joints P<0.05; cervical spine,
elbow, wrist, knee and ankle joints P<0.001) (Figure 2). There
was a trend for more severe ROM abnormalities on the right side.
Conclusions: In a cohort from the Kashin-Beck Disease region
of central China, brachydactyly was associated with more severe
joint ROM abnormalities of all major joint groups except the hip.
These data demonstrate the widespread and severe nature of
the KBD osteoarthropathy as well as the utility of the feature of
brachydactyly to identify a more severely affected subgroup.
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Purpose: One objective of disease modifying drugs in osteoarthri-
tis is to slow cartilage degeneration. Our goal was to determine
efﬁcacy and toxicity thresholds under which disease modifying
osteoarthritis drugs (DMOADs) would be a cost-effective addition
to the current management of knee OA.
Methods: We developed a computer simulation model of the nat-
ural history and management of knee OA. We considered a pop-
ulation with a mean age of 62 and symptomatic knee OA equally
distributed between K-L 2 and 3. We based the standard of care
for knee OA on ACR treatment guidelines, including pain man-
agement, physical therapy, nonsteroidal anti-inﬂammatory drugs
(NSAIDS), intra-articular steroid injections and total knee arthro-
plasty (TKA) for those who reached end stage (K-L 4) and were
willing to undergo surgery (∼30%, based on published literature).
We examined DMOAD characteristics along four domains: struc-
tural efﬁcacy (inhibiting progression to the next Kellgren Lawrence
(K-L) grade), pain efﬁcacy (proportion of those who experience
pain relief, independent of structural effect), toxicity, and costs. In
the base case analysis we assumed that DMOADs exhibit struc-
tural efﬁcacy of 50%, pain efﬁcacy of 20% and severe toxicity of
0.5%/year at annual cost of $1,000. This toxicity level is consis-
tent with the toxicity of biologic therapy for RA. Cost-effectiveness
of DMOADs was estimated as the ratio of incremental costs to
incremental effectiveness (difference in quality-adjusted life years,
QALYs) when DMOADs were added to the current standard of care
for knee OA. Both costs and quality adjusted life expectancy were
discounted at 3% per year. We used the WHO’s recommended
threshold for cost-effectiveness (3x per capita GDP=$144,000 in
the US). In sensitivity analyses we varied the structural efﬁcacy
from 25-75%, pain efﬁcacy from 0-50%, toxicity from 0.1-2% and
annual costs from $1,000-$5,000.
Results: In the base case analysis, DMOADs led to a mean
improvement of 0.03 QALYs at an additional cost of $3,526,
resulting in a cost-effectiveness ratio of $136,000/QALY. Reducing
the annual risk of major toxicity to 0.1% led to a cost-effectiveness
ratio of $91,000/QALY. Reductions in pain efﬁcacy below 20%
or increases in toxicity rates above 0.5%/year led to an overall
decrease in QALYs while increasing the cost of OA management
in strategies containing DMOADs compared to current standard of
care. The cost-effectiveness of DMOADs improved if pain efﬁcacy
increased above 20%. (Figure) DMOADs priced at $5,000 per year
reached the cost-effectiveness threshold only when they carried
no toxicity and were accompanied by both structural and pain
efﬁcacy of at least 75%.
Conclusions: Disease modifying regimens focused on slowing
progression of symptomatic knee OA may improve quality ad-
justed life expectancy at cost-effectiveness levels comparable to
